India Pharma Outlook: Tariffs, CDMO Boom & Hospital Growth | JM Financial’s View On China & US　 #ETNOW

India Pharma Outlook: Tariffs, CDMO Boom & Hospital Growth | JM Financial’s View On China & US
JM Financial’s Pharma Analyst Amey Chalke breaks down the real impact of Trump’s tariff threat on branded and specialty pharma, why earnings risk remains limited, and how Q2 numbers reaffirm a clear sector pecking order: Hospitals → CDMOs → Pharma Generics. He also explains why China+1 is a structural multi-year tailwind, why larger CDMOs will scale faster, concerns for FY27 earnings in big generics, and how India retains its cost and capability advantage despite global uncertainty.

#etnow #cdmo #hospitals #jmfinancial #trumptariffs #pharma #pharmasector #earnings #generics #us #china

YouTube Channel – https://www.youtube.com/@ETNow

Subscribe To ET Now For Latest Updates On Stocks Market News , Business News, Company News, IPO & More | https://bit.ly/SubscribeToETNow

Subscribe Now To Our Network Channels :-
ET Now Swadesh: https://www.youtube.com/etnowswadesh
Times Now: http://goo.gl/U9ibPb

Social Media Links :-
Twitter – http://goo.gl/hA0vDt
Facebook – http://goo.gl/5Lr4mC

Website – https://ift.tt/dJBqfGj

Follow us on Google News for latest updates
ET Now: https://ift.tt/ZrizBb3
Times Now Navbharat: https://bit.ly/3zDaKJo
Times Now : https://bit.ly/3CyrrYg
Zoom: https://bit.ly/3CEK0dv
Chapters:
0:00 Understanding the Impact of Tariffs on Indian Pharma
1:40 Analyzing Q2 Earnings: Hospitals vs. Pharma
2:40 China Plus One Strategy: Long-Term Implications for Indian Pharma
3:45 Identifying Key Players in the CDMO and Hospital Sectors
4:36 Evaluating Q2 Results: Changes in Sector Conviction
6:10 India’s Position in the Global Pharmaceutical Market
7:29 Shifting Focus: India’s Transition to Value-Driven Products
8:12 Earnings Estimates Post Q2: Sector Overview and Insights

Thank you for your support in keeping this website running.💛

View on “Tokyo Trend News”